Leading Musculoskeletal Ultrasound AI Company Shizhijue Completes New Funding Round Within Four Months and Files IPO Prospectus

VCBeat learned at the earliest opportunity that on March 14, 2025, a leading enterprise in ultrasound AIBeijing Shizhijue Intelligent Technology Co., Ltd. (hereinafter referred to as “Shizhijue”)Announces Completion of New Round of Financing, with Investors BeingHongchuang Capital. This is SHIZHIJUEFollowing the financing secured from Yishang Huicheng last November, a new round of financing was rapidly completed within four months., which fully reflects the recognition of the value of the ultrasound AI sector by professional healthcare funds, and also demonstrates the company management’s clear strategy and efficient execution capabilities.RCCAPITALContinuing to serve SHIZHIJUE’s financing by acting as its long-term exclusive financial advisor.

SHIZHIJUEBeijing Shizhijue Intelligent Technology Co., Ltd. was established in May 2023, with the mission of promoting the widespread adoption of ultrasound applications in clinical departments through AI technology. Since its inception, the company has achieved rapid development through close collaboration with the Musculoskeletal and Superficial Ultrasound Committee of the Chinese Research Hospital Association, the Institute of Automation of the Chinese Academy of Sciences, Beijing Chaoyang Hospital Affiliated to Capital Medical University, and several other top-tier Grade A tertiary hospitals. The company has formed a product layout characterized as “One Horizontal, Eight Verticals,” with ultrasound medicine serving as the “horizontal” axis, and pain management, anesthesiology, rehabilitation, traditional Chinese medicine, rheumatology and immunology, emergency medicine, neurology, and trauma orthopedics constituting the eight “vertical” axes.

Director Guo Ruijun Delivers Speech at Bali Corporate Forum

SHIZHIJUE's flagship product isMusculoskeletal Ultrasound Real-Time Dynamic Artificial Intelligence (AI)-Assisted Diagnosis and Treatment System—Zhiying,It is the industry’s first AI-powered musculoskeletal ultrasound product that integrates teaching and training, assisted diagnosis, and assisted therapy. Tailored to the specific needs of musculoskeletal ultrasound, it has sequentially developed key features such as real-time dynamic visualization of living anatomical structures, comparison of physiological parameters between healthy and affected sides, color flow index detection, standard plane references, and anatomical prompts. Currently, AI modules for the shoulder, elbow, wrist, hip, knee, ankle, and neck have been completed, while those for the chest, lumbar spine, sacrum, head and face, and chest wall are under rapid development. In addition, precision diagnosis and treatment modules designed for pain management and anesthesiology departments provide physicians with a comprehensive and efficient musculoskeletal ultrasound diagnosis and treatment platform, significantly shortening the learning curve. The product is compatible with mainstream high-end ultrasound systems on the market as well as major domestically produced portable ultrasound devices, thereby accelerating the adoption and capability of musculoskeletal ultrasound diagnosis and treatment in hospitals nationwide.

Visual Perception Musculoskeletal Ultrasound AI (Zhiying) and Its Efficacy

To facilitate the broader adoption and application of ultrasound AI, SHIZHIJUE has developedAI-Powered Visual Diagnostic Device Based on Handheld Ultrasound — ZhiMouBased on the limited hardware capabilities of handheld ultrasound devices, the AI Visualizer can clearly present dynamic segmented images of joints, bones, and surrounding neurosoft tissues. By leveraging artificial intelligence algorithms, it transforms complex and difficult-to-interpret ultrasound images into gross anatomical segmentation images that are easily recognizable by laypersons, enabling real-time dynamic image recognition of soft tissues such as bones, muscles, tendons, and ligaments in the scanned area. The SHIZHIJUE AI Visualizer is characterized by its portable design concept, which imposes no restrictions on usage locations. It allows for rapid on-site visualization and structural feature recognition of the examined areas (including bones, joint capsules, tendons, ligaments, and muscles), thereby providing scientific guidance for subsequent rehabilitation therapy and training.

SHIZHIJUE AI Visual Diagnostic Device (ZhiMou)

To address scenarios that demand both convenience and higher image quality, SHIZHIJUE has also developedAI-Integrated Portable Ultrasound Device: ZhiJue. This product not only delivers image quality sufficient for more precise clinical diagnosis and treatment, but also integrates an AI server, monitor, and portable ultrasound device into a single unit, greatly enhancing convenience for clinical departments and streamlining the hospital procurement process.

Visual Perception AI Portable Ultra (ZhiJue)

As a common complementary product for ultrasound AI, SHIZHIJUE has also launched high-quality medical consumables:Disposable Sterile Kit for Platelet-Rich Plasma (PRP) Preparation, i.e., PRP Separation Kit—JunStyle,It is a specialized tool for preparing platelet-rich plasma (PRP). Under the guidance of clinicians, it is suitable for various conditions requiring tissue regeneration and repair, such as osteoarthritis, tendinopathy, local tissue injury repair, and wound healing. The device is easy to operate, strictly adheres to medical standards, and provides robust support for PRP therapy.

Visual Perception PRP Separation Kit (JunStyle)

SHIZHIJUE boasts a prestigious founding team. Mr. Zhang Chen, the Chairman, previously served as the Head of Sales at an AI healthcare unicorn company, where he expanded business to over 300 Grade A tertiary hospitals. General Manager Dr. Guo Ruijun formerly served as Director of the Department of Ultrasound Medicine at Beijing Chaoyang Hospital and is the Chairperson of the Musculoskeletal and Superficial Ultrasound Professional Committee of the Chinese Research Hospital Association. Chief Technology Officer Mr. Jiang Yongshi, a renowned expert in graphics, imaging, and artificial intelligence, was a Senior Researcher at the Institute of Automation, Chinese Academy of Sciences (CASIA), and received the First Prize for Scientific and Technological Progress from the People's Liberation Army. Additionally, Mr. Yang Yiping, former Deputy Director of CASIA, serves as a key scientific advisor to the company.

Core Team

About This Financing Round, Mr. Zhang Chen, Chairman of SHIZHIJUEStatement: We express our gratitude to Hongchuang Capital for its selection of and trust in our company. The professionalism and diligence of the Hongchuang team are truly admirable. We also thank RCCAPITAL for its professional services during the financing process. Having been engaged in the sales of ultrasound AI products for six years, I have gained profound insights into the integration of ultrasound with clinical practice and have closely monitored the development of related products within the industry. It is often stated that the penetration of ultrasound into clinical departments is a major trend; however, upon careful examination, it becomes evident that musculoskeletal ultrasound is the primary need in numerous departments, including pain management, anesthesiology, emergency medicine, rehabilitation, and traditional Chinese medicine. Meanwhile, there is a scarcity of clinicians who are proficient in interpreting and applying musculoskeletal ultrasound for disease diagnosis and treatment. Musculoskeletal ultrasound AI products genuinely empower multiple departments to conduct ultrasound-guided diagnosis and therapy. Our ability to rapidly enter over 100 hospitals and more than ten clinical departments during our promotional efforts further corroborates the widespread and essential nature of this clinical demand. Following this round of financing, we will further expand our product module layout, accelerate market promotion and hospital adoption, strengthen collaborations with high-quality resources across all parties, and thereby enhance our company’s leading advantage and brand influence.

Mr. Lu Xiaobo, Partner at Hongchuang Capital, an investor in this roundIt is indicated that: Due to the complex musculoskeletal anatomical structures, which are difficult to identify in ultrasound images, SHIZHIJUE’s AI-powered musculoskeletal ultrasound and visual diagnostic devices can address the significant challenges associated with the clinical application of musculoskeletal ultrasound. Musculoskeletal ultrasound diagnosis and treatment are widely used in numerous outpatient departments, including pain management, rehabilitation, anesthesiology, traditional Chinese medicine, and ultrasound-guided intervention, and can be extensively deployed in primary care hospitals. SHIZHIJUE has a well-balanced commercial, clinical, and technical team. Its products meet the needs of various departments and clinicians across different scenarios. The company possesses strong data and technological barriers, along with robust commercialization capabilities, making it possible to achieve visualization in pain management (anesthesiology), quantification in rehabilitation, and minimally invasive procedures in surgery. It is poised to become the most successful enterprise in the commercialization of AI-driven musculoskeletal ultrasound imaging.

Exclusive Financial Advisor: Ms. Yan Guopei, Head of RCCAPITAL’s Northern RegionIt indicates that the most significant trend in ultrasound equipment is its integration with clinical diagnosis and treatment. Whether it is AI lowering the barrier to interpreting ultrasound images or the emergence of various new types of probes, developments are centered around this trend. SHIZHIJUE has accurately grasped this trend. Leveraging its robust physician resources and leading AI technology, the company rapidly completed product development and iteration, and quickly expanded its market presence through strong execution capabilities. Mr. Zhang Chen, Chairman of SHIZHIJUE, and his core team possess serial entrepreneurship experience. Their in-depth thinking on product form, technological advantages, and business models has continuously unlocked growth potential for the company. RCCAPITAL is honored to have assisted SHIZHIJUE in completing the entire process of this financing round—from scheme design to fund settlement—within four months. During this period, technical operations such as the acquisition of a consumables company and equity participation by key team members were also implemented, paving the way and providing support for the company’s future development in the capital markets.

SHIZHIJUEBeijing Shizhijue Intelligent Technology Co., Ltd. was established in May 2023 and is a high-tech enterprise located in Zhongguancun. Adhering to the philosophy of “integration of medicine and intelligence,” the company, guided by medical experts from the Musculoskeletal and Superficial Ultrasound Committee of the Chinese Research Hospital Association and core technical experts from the Chinese Academy of Sciences, and with strong support from numerous top-tier Grade A tertiary hospitals, has successfully developed a real-time dynamic AI-assisted diagnostic and therapeutic system for musculoskeletal ultrasound. It has also launched an AI-powered visual stethoscope based on handheld ultrasound, offering more convenient and flexible usage scenarios, as well as AI-enabled portable ultrasound devices that meet both convenience and higher image quality requirements. These innovations provide clinicians and sonographers with modules for detailed in vivo anatomical visualization (covering six major joints) and precise diagnosis and treatment, significantly shortening the learning curve and improving work efficiency. The advent of the musculoskeletal ultrasound AI system makes it possible to visualize pain (anesthesiology), quantify rehabilitation, minimize surgical invasiveness, refine internal medicine practices, and enable wearable and home-use ultrasound. Furthermore, Shizhijue has proudly launched its independently developed high-quality medical consumables compatible with musculoskeletal ultrasound AI: the JunStyle Disposable Sterile Kit for Platelet-Rich Plasma (PRP) Preparation, providing more convenient and efficient supporting products for visually guided, minimally invasive regenerative pain therapy.

Hongchuang Capital is a professional healthcare equity investment firm focused on early-stage commercialization investments, founded by Mr. Lu Xiaobo, former Healthcare Partner at Sequoia Capital. With 15 years of extensive experience in healthcare commercialization and 13 years of frontline investment experience in both RMB and USD funds, Mr. Lu previously served as Healthcare Partner at two leading firms, Cowin Capital and Sequoia Capital. He has led investments in over 50 healthcare projects, 13 of which have successfully achieved IPOs on the A-share market, delivering substantial returns to investors. The Hongchuang team possesses diverse, multidisciplinary expertise spanning medical devices, in vitro diagnostics (IVD), biopharmaceuticals, commercialization, and financial investment. The firm excels at helping portfolio companies enhance their core competitiveness from multiple dimensions, including technological innovation, business strategy, and capital markets. Committed to long-term value creation, Hongchuang Capital continuously seeks out early-to-mid-stage projects with differentiated commercial potential, diligently pursuing "non-consensus dividends."

RCCAPITAL is a boutique investment bank characterized by rapid fundraising. Its financing solutions encompass comprehensive services, including strategic planning, growth pathways, and corporate governance, thereby achieving greater efficiency in subsequent channel matching and deal facilitation to help clients secure funding more quickly and with greater certainty. The RCCAPITAL team is based in Beijing, Shanghai, and Hangzhou, with core members hailing from boutique investment banks, consulting firms, accounting firms, and biotechnology companies. Since its establishment, the firm has cumulatively assisted clients in raising billions of yuan. RCCAPITAL focuses on the healthcare and broader health sectors, serving clients across medical AI, diagnostics, medical devices, biotechnology, new drug R&D, CXO, healthcare services, hospital IT, innovative payment solutions, and consumer healthcare.